+ Bookmark This Page    
Preferences  |  9:15 PM
  1. Home
  2. Latest Press Releases
  3. Submit Press Releases
  1. PR Home
  2. News Archive
  3. By Category
  4. By Location
  5. By Date
  6. By Tag
  7. Newsletter
  8. 40,000 RSS Feeds
  9. Submit Free Press Release
   
Filter News
Show All Results

Show Filtered Results

Category
- Science (x)

Country
- Hong Kong (x)

State / Province
(To see all states,
remove category filter)


City / Town
Select State First

Vaxin’s Pandemic Vaccine Spotlighted

Promising data presented at Immunotherapeutics & Vaccine Summit
 

FOR IMMEDIATE RELEASE

PR Log (Press Release)Aug 13, 2008 – Contact:
Bill Enright
President & CEO
Phone: 205-909-3751
Email: enright@vaxin.com

FOR IMMEDIATE RELEASE

VAXIN’S PANDEMIC VACCINE SPOTLIGHTED

Promising data presented at Immunotherapeutics & Vaccine Summit

Birmingham, Alabama --August 13, 2008—Vaxin’s lead vaccine candidate, targeting avian influenza, is being featured today at the Immunotherapeutics & Vaccine Summit in Boston.  Kent Van Kampen, Vaxin’s Chief Operating Officer and a highly respected authority on vaccine development, will be presenting the company’s recent findings.  

Responding to the ongoing international concern that a particularly virulent form of avian influenza may become highly infectious in humans, Vaxin has developed a vaccine which can be rapidly produced and mass administered.  “Our vaccine uses a neutered cold virus to carry a tiny snippet of influenza DNA, rather than the entire influenza virus,” said Dr. Van Kampen.  “When the immune system responds, it actually learns how to be immune to the target disease – avian influenza in this case,” he said.

This vaccine has already been shown to provide excellent protection when administered to poultry before hatching, a technique called in-ovo vaccination which is well suited for automation.  Vaxin has utilized these advances to develop a version of the vaccine that will soon be tested in humans.  Dr. Van Kampen said, “We have data from a previous human trial which demonstrated a promising immune response against a seasonal flu strain  and we have high expectations for our upcoming pandemic flu vaccine trial.”

Billed as the "Leading International Vaccine Event", Cambridge Healthtech Institute’s Third Annual Immunotherapeutics & Vaccine Summit brings together vaccine professionals from companies, government agencies, academics, and nonprofit institutes, to discuss issues surrounding the development of today’s vaccines around the world.  “We are pleased to be able to share our progress with such a distinguished group of colleagues,” said Dr. Van Kampen.  

By protecting two routes of potential spread, humans and poultry, Vaxin’s pandemic avian influenza vaccines could provide an excellent defense against a worldwide pandemic.  The poultry vaccine would also protect a vital food industry in the process.



Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected.  These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

#   #   #

# # #

About Vaxin:

Vaxin Inc. is an emerging vaccine company with a lead in the development of needle-free, single dose highly effective vaccines. These vaccines are safely administered into the nose or onto the skin, taking the battle against diseases to the immune system’s front lines where diseases attack, rather than injecting the vaccine inside the body where the body’s immune response is actually weaker. This also allows Vaxin’s vaccines to be mass administered by personnel without sophisticated medical training.

The company’s technology platform also provides a critical tool for the rapid production of vaccines against influenza, avian influenza, anthrax, and Alzheimer’s disease utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin’s vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics. Vaxin’s technology also has applications for animal health uses.


To embed this press release, copy and paste the following HTML code into your webpage-
# # # Click to see PDF Version of this Press Release

Email to a Friend     Visit Press Room       Previous News   Next News


Email Contact:Click to email
Issued By:Vaxin Inc.
Phone:205-909-3751
Address:1500 First Avenue North, Ste. D126
City/Town:Birmingham
State/Province:Alabama
Zip:35203
Country:United States
Categories:Health
Tags:adenovirus, clinical, influenza, pandemic, vaccine, vaxin, vector
Last Updated:Aug 13, 2008
Shortcut:http://prlog.org/10104386

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog.Org can't be held liable for the contents of the press releases.   Report Abuse


Latest Press Releases From “Vaxin Inc”


Upcoming Press Releases...


Most Viewed Weekly

Secret Service Investigation, Class Action Lawsuit, Cast Shadow Over Radiant Systems and Distributo - 2377 views

Passions Peak at BITS Pilani Graduating Students Farewell Tea Party - 706 views

For Alam Ali Kayam Khan to do SRK BITS Pilani says Main Hoon Na - 684 views

Ellen Pompeo Welcomes Baby Girl; Mom-Entrepreneurs Rush to get Products to the new mom, STAT - 608 views

Microsoft SharePoint’s Market Intelligence Capabilities Enhanced through Intelligence Plaza - 429 views


Daily News!

Baby Swags Launches New Tween/Teen Online Guide

Proud to be BITSian Anu Hassan wins Kalaimamani Award

ELEMENTS OF NATURE by Jerry Cayzer is published

Away from home or home alone, DirectBuy of Buffalo helps burglar-proof your house for the holidays

Brothersoft Awards 2009 opens to vote

Previous   Next

Aug 13, 2008 News

Aug 2008 News

Are you a Journalist?

For Businesses ...

Tutorial on Free Marketing


November 2009
Su Sa Fr Th We Tu Mo
29 28 27 26 25 24 23
22 21 20 19 18 17 16
15 14 13 12 11 10 9
8 7 6 5 4 3 2



  1. SiteMap
  2. Contact PR Log
  3. Privacy Policy
  4. Terms of Use
  5. Copyright Notice